Announcements Trials
Browse Landscape

Status

Completed 3Withdrawn 1Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2INDIV 1

Study Type

Interventional 325Observational 6

Sponsor

Cancer Type

Thoracic 18Dermatologic 11Gastrointestinal 7Head & Neck 6Genitourinary 6Breast 2Tumor-Agnostic 1Other 1CNS 1

Conditions

Carcinoma, Renal Cell 3Lung Neoplasms 2Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Melanoma 1Kidney Neoplasms 1Colorectal Neoplasms 1Advanced Renal Cell Carcinoma (aRCC) 1Adenocarcinoma 1

Interventions

Surveys and Questionnaires 52Blood Specimen Collection 47enzalutamide 29radium Ra 223 dichloride 22Biopsy 20darolutamide 19Radiotherapy 19Docetaxel 19apalutamide 18Sunitinib 18Magnetic Resonance Spectroscopy 18Sorafenib 17Abiraterone Acetate 17Watchful Waiting 16Interviews as Topic 15Gene Expression Profiling 15Amplified Fragment Length Polymorphism Analysis 15Observation 13Leuprolide 13Immunohistochemistry 13Androgen Antagonists 13acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 12Magnetic Resonance Imaging 12avelumab 11Specimen Handling 11abiraterone 9Polymerase Chain Reaction 9Flow Cytometry 9Radiosurgery 8Microarray Analysis 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Observational × pembrolizumab × Genitourinary × Clear all
NCT05287464 2025-11-26

International Multicentric Study ARON-1

Hospital of Macerata

Recruiting
1,220 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT06345183 2025-11-06

Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

Bristol-Myers Squibb

Completed
327 enrolled
Genitourinary

Advanced Renal Cell Carcinoma (aRCC)

NCT04682587 2025-01-03

To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma

Pfizer

Completed
481 enrolled 14 charts
Genitourinary

Carcinoma, Renal Cell

NCT04555603 2023-11-21

Axitinib Therapy Management Study

Pfizer

Withdrawn
Genitourinary

Carcinoma, Renal Cell

NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

Cambridge University Hospitals NHS Foundation Trust

Unknown
1,800 enrolled
DermatologicGenitourinaryThoracic

Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT03695835 2020-07-22

NIRPA

Gary Onik MD

Completed
27 enrolled
GastrointestinalGenitourinaryThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡